Get notified regarding key financial metrics and revenue changes at Aratana TherapeuticsLearn more
Banner background

Aratana Therapeutics Revenue

Aratana Therapeutics revenue was $35.41 m in FY, 2018

Embed Graph

Summary - Funding Rounds

Founding Date

2010

Total Funding

$76.8 m

Investors

Aratana Therapeutics is a subsidiary of Elanco

Aratana Therapeutics Income Statement

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

176.0k300.0k43.0k156.0k230.0k229.0k172.0k38.0m40.0k3.8m5.2m6.2m4.0m4.9m21.6m7.4m

Cost of goods sold

110.0k109.0k138.0k19.0k1.7m286.0k3.1m3.7m3.7m536.0k1.3m2.2m1.5m

Gross profit

46.0k121.0k91.0k153.0k36.3m(246.0k)701.0k1.5m2.5m3.5m3.6m19.4m5.8m

Gross profit Margin, %

29%53%40%89%95%(615%)18%28%40%87%73%90%79%

R&D expense

2.5m3.2m3.6m4.3m6.1m6.2m6.1m6.2m10.7m5.3m5.3m4.7m3.7m3.2m2.2m1.6m1.5m1.8m

General and administrative expense

1.3m1.4m4.6m4.4m3.9m4.2m4.9m5.0m6.6m6.1m6.9m7.5m6.9m6.9m7.7m6.7m7.0m9.2m

Operating expense total

3.7m4.7m8.2m8.7m10.0m10.9m11.5m55.1m17.4m14.3m12.4m12.5m11.1m10.7m11.3m9.3m10.0m12.8m

Depreciation and amortization

539.0k617.0k581.0k483.0k483.0k483.0k95.0k95.0k91.0k64.0k86.0k85.0k130.0k129.0k129.0k143.0k

EBIT

(3.7m)(4.7m)(9.2m)(9.5m)(10.5m)(10.9m)(11.3m)(55.0m)(17.3m)22.0m(12.6m)(11.8m)(9.6m)(8.2m)(7.8m)(5.7m)9.4m(7.0m)

EBIT margin, %

(5240%)(3168%)(24488%)(6963%)(4933%)(24021%)(10035%)58%(31535%)(312%)(186%)(133%)(194%)(117%)44%(95%)

Interest expense

78.0k10.0k557.0k110.0k201.0k1.8m3.0m193.0k807.0k764.0k757.0k777.0k790.0k737.0k715.0k647.0k558.0k175.0k

Interest income

22.0k26.0k14.0k13.0k31.0k71.0k43.0k33.0k77.0k83.0k116.0k85.0k88.0k138.0k141.0k141.0k159.0k174.0k

Pre tax profit

(9.8m)(9.6m)(10.7m)(9.0m)(8.3m)(55.2m)(18.1m)21.2m(13.4m)

Income tax expense

(627.0k)(335.0k)(601.0k)(271.0k)(360.0k)(758.0k)

Net Income

(3.4m)(4.7m)(9.2m)(9.3m)(10.7m)(8.8m)(8.0m)(54.4m)(18.1m)21.2m(13.4m)(12.6m)(10.4m)(8.9m)(8.5m)(6.4m)8.8m(6.8m)

Aratana Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

41.1m9.8m26.8m87.3m66.9m41.4m

Accounts Receivable

352.0k60.0k87.0k2.4m2.2m

Prepaid Expenses

274.0k900.0k1.5m1.6m1.8m

Inventories

55.0k427.0k1.3m11.1m13.6m11.4m

Current Assets

48.5m99.9m89.0m101.5m85.2m58.1m

PP&E

98.0k620.0k2.6m1.9m1.2m693.0k

Goodwill

20.8m41.4m39.8m39.4m41.3m40.8m

Total Assets

115.5m207.9m147.1m151.4m135.2m106.4m

Accounts Payable

2.3m1.5m1.4m7.4m7.5m911.0k

Short-term debt

8.6m17.3m

Current Liabilities

16.9m9.5m5.7m34.7m35.5m5.6m

Long-term debt

Total Debt

17.3m

Total Liabilities

29.5m26.1m45.5m61.0m55.1m5.6m

Common Stock

23.0k34.0k35.0k43.0k48.0k

Additional Paid-in Capital

112.5m255.0m263.9m286.9m321.6m350.7m

Retained Earnings

(68.0m)(152.0m)(185.6m)(233.3m)(241.2m)

Total Equity

86.0m181.8m101.6m90.4m80.1m100.8m

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.3 x1.1 x1.4 x1.7 x1.7 x1.1 x

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

14.3m46.2m76.7m68.3m56.8m30.2m12.6m13.5m13.8m108.8m100.8m67.5m78.8m68.8m66.4m59.3m54.3m36.6m

Accounts Receivable

147.0k387.0k90.0k115.0k148.0k134.0k11.0k17.0k15.0k3.5m4.9m9.4m2.4m2.8m19.6m4.9m

Prepaid Expenses

2.9m305.0k679.0k764.0k614.0k1.0m927.0k1.1m1.9m1.6m3.0m1.3m6.6m1.8m1.3m928.0k1.7m1.2m

Inventories

125.0k124.0k203.0k645.0k882.0k1.2m2.4m2.6m5.6m9.1m7.0m9.0m14.0m15.2m13.7m10.8m

Current Assets

23.1m52.6m82.3m73.4m110.5m89.4m85.7m75.3m77.1m113.7m110.9m81.9m98.8m90.7m84.6m79.0m91.1m53.9m

PP&E

18.0k21.0k366.0k508.0k741.0k614.0k1.6m2.3m2.4m2.3m2.1m1.6m1.5m1.3m1.0m929.0k811.0k575.0k

Goodwill

38.5m38.4m37.1m39.6m40.2m40.2m40.5m40.0m40.3m39.6m40.5m41.0m41.7m40.8m40.8m40.8m

Total Assets

23.3m52.7m197.4m187.9m221.3m193.3m186.9m133.4m136.0m168.9m167.3m134.7m152.7m145.0m134.7m128.0m139.8m104.7m

Accounts Payable

1.8m816.0k1.4m991.0k1.9m2.1m1.7m1.2m6.4m7.3m5.1m1.2m1.9m3.4m1.9m1.1m657.0k3.0m

Short-term debt

1.9m1.9m13.1m

Current Liabilities

5.0m5.1m14.6m8.6m9.9m5.7m20.9m5.4m8.6m21.1m21.4m30.7m23.3m26.5m25.1m26.1m28.7m8.1m

Long-term debt

398.0k

Total Debt

1.9m1.9m13.1m398.0k

Total Liabilities

9.4m8.8m28.3m27.9m28.3m21.8m21.8m20.5m49.1m59.2m56.1m53.6m52.7m51.3m39.0m34.5m31.4m8.5m

Common Stock

1.0k21.0k29.0k29.0k34.0k34.0k34.0k35.0k35.0k35.0k36.0k37.0k42.0k43.0k46.0k47.0k48.0k48.0k

Additional Paid-in Capital

910.0k77.4m205.3m206.8m253.1m257.4m259.5m261.8m266.2m268.4m283.0m290.1m318.0m319.8m338.5m343.6m349.7m353.1m

Retained Earnings

(44.9m)(55.1m)(76.7m)(84.7m)(139.2m)(170.1m)(148.9m)(162.3m)(198.4m)(208.8m)(217.7m)(235.1m)(241.4m)(232.6m)(248.0m)

Total Equity

(28.0m)43.8m169.1m160.1m193.0m171.5m165.1m113.0m86.9m109.6m111.2m81.1m100.0m93.7m95.6m93.5m108.4m96.2m

Debt to Equity Ratio

-0.1 x0 x0.1 x0 x

Debt to Assets Ratio

0.1 x0 x0.1 x0 x

Financial Leverage

-0.8 x1.2 x1.2 x1.2 x1.1 x1.1 x1.1 x1.2 x1.6 x1.5 x1.5 x1.7 x1.5 x1.5 x1.4 x1.4 x1.3 x1.1 x

Aratana Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(4.3m)(38.8m)(84.1m)(33.6m)(47.5m)(14.7m)

Depreciation and Amortization

395.0k2.0m1.8m991.0k1.2m990.0k

Accounts Receivable

(102.0k)281.0k(27.0k)(2.3m)202.0k

Inventories

(372.0k)(879.0k)(15.0m)(3.2m)(499.0k)

Accounts Payable

1.5m(1.1m)(117.0k)6.2m62.0k(6.5m)

Cash From Operating Activities

(16.2m)(32.2m)(38.5m)(11.3m)(38.2m)(11.3m)

Purchases of PP&E

(94.0k)(471.0k)(2.2m)(72.0k)(1.0k)

Cash From Investing Activities

(29.2m)(100.1m)33.7m57.3m(5.8m)(493.0k)

Long-term Borrowings

(3.5m)(36.5m)

Dividends Paid

Cash From Financing Activities

72.5m101.0m21.9m14.6m23.5m(13.7m)

Net Change in Cash

27.1m(31.3m)16.9m60.6m(20.4m)(25.4m)

Interest Paid

357.0k942.0k1.1m2.9m3.0m4.0m

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(6.7m)(11.4m)(9.2m)(18.4m)(28.6m)(8.8m)(16.8m)(71.2m)(18.1m)3.1m(10.2m)(12.6m)(23.0m)(31.9m)(8.5m)(14.9m)(6.1m)(6.8m)

Depreciation and Amortization

6.0k9.0k566.0k1.2m1.9m520.0k1.1m1.6m244.0k493.0k738.0k392.0k605.0k928.0k249.0k496.0k743.0k261.0k

Accounts Receivable

125.0k(116.0k)174.0k227.0k194.0k208.0k49.0k43.0k45.0k(3.5m)(4.8m)(9.3m)(32.0k)(429.0k)(17.2m)(2.7m)

Inventories

(70.0k)(69.0k)(148.0k)(218.0k)(455.0k)(746.0k)(1.0m)(2.8m)(5.8m)2.1m4.2m1.7m(376.0k)(2.0m)(1.4m)597.0k

Accounts Payable

1.1m36.0k(1.3m)(1.7m)(763.0k)630.0k213.0k(274.0k)5.0m5.9m3.7m(6.2m)(5.5m)(4.0m)(5.6m)(6.3m)(6.8m)58.0k

Cash From Operating Activities

(8.5m)(10.9m)(8.2m)(15.9m)(22.8m)(9.0m)(17.8m)(28.1m)(13.4m)23.3m5.2m(18.4m)(29.9m)(38.5m)(13.2m)(19.4m)(23.8m)(5.5m)

Purchases of PP&E

(8.0k)(14.0k)(67.0k)(246.0k)(634.0k)(49.0k)(1.1m)(1.9m)(6.0k)(19.0k)(25.0k)(11.0k)(16.0k)

Cash From Investing Activities

485.0k375.0k(13.4m)(13.1m)(62.5m)32.5m23.6m34.6m442.0k58.7m56.9m(2.5m)(3.5m)(3.5m)249.0k3.0k(989.0k)744.0k

Short-term Borrowings

(3.0m)(7.5m)(12.0m)

Cash From Financing Activities

8.4m42.7m57.3m56.2m101.0m(3.0m)(3.0m)(2.7m)1.0k11.9m1.2m24.9m23.6m12.5m11.8m12.2m(123.0k)

Net Change in Cash

376.0k32.2m35.7m27.2m15.7m20.3m2.8m3.7m(12.9m)82.0m74.1m(19.8m)(8.5m)(18.5m)(441.0k)(7.6m)(12.6m)(4.9m)

Interest Paid

91.0k161.0k386.0k413.0k584.0k206.0k415.0k628.0k721.0k1.4m2.2m733.0k1.5m2.2m728.0k1.4m2.0m

Aratana Therapeutics Ratios

USDQ2, 2013

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-0.8 x